^
Association details:
| Biomarker: | MET mutation |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug: | foretinib (GSK1363089) (c-MET inhibitor, VEGFR-2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma
Excerpt:
The presence of a germline MET mutation was highly predictive of a response (five of 10 v five of 57 patients with and without germline MET mutations, respectively)....Foretinib demonstrated activity in patients with advanced PRCC with a manageable toxicity profile and a high response rate in patients with germline MET mutations.
DOI:
10.1200/JCO.2012.43.3383
Trial ID:
